Fifth AZ cancer drug gets FDA breakthrough status

1 August 2017

For the second time in two days, Anglo-Swedish pharma company AstraZeneca (LSE: AZN) announced that the US Food and Drug Administration (FDA) had given Breakthrough Therapy designation to one of its oncology medicines.

In fact, acalabrutinib is the fifth AstraZeneca cancer drug to be given this status since 2014, albeit the first for the company in hematology.

"Acalabrutinib is a potent, irreversible BTK inhibitor with a high degree of specificity for its target"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK